

**Bilirubin Reduces the Uptake of Estrogen Precursors and the Followed Synthesis  
of Estradiol in Human Placental Syncytiotrophoblasts *via* Inhibition and  
Down-regulation of OAT4**

Yingqiong Zhang<sup>1,2</sup>, Yujia Chen<sup>1</sup>, Binxin Dai<sup>1</sup>, Mengru Bai<sup>2</sup>, Shuanghui Lu<sup>1</sup>,

Nengming Lin<sup>2</sup>, Hui Zhou<sup>1</sup>, Huidi Jiang<sup>1,\*</sup>

<sup>1</sup>Institute of Pharmaceutical Analysis and Drug Metabolism, College of  
Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang P.R. China;

<sup>2</sup>Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine,  
Hangzhou, Zhejiang P.R. China

**Running title:** Bilirubin inhibits and down-regulates OAT4 in PHTCs

**Corresponding author:** Huidi Jiang

**Address:** College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou 310058, China

**E-mail:** hdjiang@zju.edu.cn (H. Jiang)

**Tel (Fax):** +86-571-88208408

**16-digit ORCID of the author(s):** 0000-0002-2180-5153 (H. Jiang)

The number of text pages: 39

The number of text tables: 0

The number of text figures: 5

The number of references: 53

The number of words in the Abstract: 232

The number of words in the introduction: 582

The number of words in the discussion: 1476

## Abstract

Estrogen biosynthesis in human placental trophoblasts requires the hOAT4-mediated uptake of fetal derived precursors such as dehydroepiandrosterone-3-sulfate (DHEAS) and 16 $\alpha$ -hydroxy-DHEA-S (16 $\alpha$ -OH-DHEAS). Scant information is available concerning the contribution of fetal metabolites on the impact of placental estrogen precursor transport and the followed estrogen synthesis. This study substantiated the roles of bilirubin as well as bile acids (taurochenodeoxycholic acid, TCDCA; taurocholic acid, TCA; glycochenodeoxycholic acid, GCDCA; chenodeoxycholic acid, CDCA) on the inhibition of hOAT4-mediated uptake of probe substrate 6-carboxylfluorescein (6-CF) and DHEAS in stably transfected hOAT4-CHO cells, with the IC<sub>50</sub> of 1.53 and 0.98  $\mu$ M on 6-CF and DHEAS respectively for bilirubin, and 90.2, 129, 16.4 and 12.3  $\mu$ M on 6-CF for TCDCA, GCDCA, TCA and CDCA. Bilirubin (2.5~10  $\mu$ M) concentration-dependently inhibited the accumulation of estradiol precursor DHEAS in human choriocarcinoma JEG-3 cells (reduced by 60% at 10  $\mu$ M) and primary human trophoblast cells (PHTCs, reduced by 80% at 10  $\mu$ M). Further study confirmed that bilirubin (0.625~2.5  $\mu$ M) concentration-dependently reduced the synthesis and secretion of estradiol in PHTCs, among which 2.5  $\mu$ M bilirubin reduced the synthesis of estradiol by 30% and secretion by 35%. In addition, immunostaining and Western Blot results revealed a distinct down-regulation of hOAT4 protein expression in PHTCs pretreated with 2.5  $\mu$ M bilirubin. In conclusion, this study demonstrated that bilirubin reduced the uptake of estrogen precursors and the followed synthesis of

estradiol in human placenta *via* inhibition and down-regulation of OAT4.

### **Significance Statement**

Fetal metabolites, especially bilirubin, was first identified with significant inhibitory effects on the hOAT4-mediated uptake of estrogen precursor DHEAS in hOAT4-CHO, JEG-3 and PHTCs. Bilirubin concentration-dependently suppressed the estradiol synthesis and secretion in PHTCs treated with DHEAS, which was synchronized with the decline of hOAT4 protein expression. Additionally, those identified bile acids exhibited a weaker inhibitory effect on the secretion of estradiol.

**Abbreviations:** FBS, Fetal bovine serum; PHTCs, primary human trophoblast cells; CHO cells, Chinese hamster ovary cells; BLB, bilirubin; CA, cholic acid; TCA, taurocholic acid; TCDCA, taurochenodeoxycholic acid; GCA, glycocholic acid; GCDCA, glycochenodeoxycholic acid; CDCA, chenodeoxycholic acid; GDCA, glycodeoxycholic acid; TDCA, taurodeoxycholic acid; DHEAS, dehydroepiandrosterone-3-sulfate; 16 $\alpha$ -OH-DHEAS, 16 $\alpha$ -hydroxy-DHEAS; ICP, intrahepatic cholestasis; PE, preeclampsia; 6-CF, 6-carboxylfluorescein.

**Keywords:** bilirubin, bile acids, OAT4 transporter, placenta, dehydroepiandrosterone-3-sulfate, estrogen

## Introduction

Human placental trophoblasts depend largely on the supply of external precursors such as dehydroepiandrosterone-3-sulfate (DHEAS) and 16 $\alpha$ -hydroxy-DHEAS (16 $\alpha$ -OH-DHEAS) for further synthesis of estrogens with advancing gestation (Morel et al., 2016). It has been shown that both fetal and maternal precursor DHEAS are used in about equal proportions in the biosynthesis of estrone (E1) and estradiol (E2), while 90% of the fetal-derived 16 $\alpha$ -OH-DHEAS for the formation of estriol (E3) which increases drastically with fetal development, are of fetal origin (Pasqualini, 2005). Serving as the main source of maternal estrogens, the placenta exquisitely expresses organic anion transporter 4 (OAT4) and organic anion transporting polypeptide 2B1 (OATP2B1, former name OATP-B) which are closely involved in the placental uptake of fetal derived hydrophilic steroid sulfates in cytotrophoblast membranes and at the basal surface of the syncytiotrophoblast (Schweigmann et al., 2014; Tomi et al., 2015), permitting temporary but significant biological functions during gestation. Former studies have ascertained that OAT4 contributes to the transport of DHEAS and exclusively mediates the uptake of 16 $\alpha$ -OH-DHEAS (Schweigmann et al., 2014; Tomi et al., 2015).

Fetal-derived potentially toxic cholephilic organic anions such as biliary pigments and bile acids cannot be disposed by the immature fetal liver, thus the placenta and the maternal liver play a key role in the metabolism and excretion of those metabolic waste. Owing to the active heme catabolism and the following high rate of bilirubin

production, together with a low expression of bilirubin uridine diphosphate-glucuronosyl transferase in the fetal liver, unconjugated bilirubin mostly binding to serum albumin or  $\alpha$ -fetoprotein (Yutaka Aoyagi, 1979), has higher concentrations in fetal than in maternal serum (Macias et al., 2009). Fetal derived bile acids from the meconium and the gallbladder have been identified in several studies (Colombo C., 1988; Naritaka et al., 2015) using liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS), which enabled us to elucidate the developmental process of fetal bile acid metabolism reflecting fetal physiological conditions. Unlike human adults, fetal bile acids are mainly conjugated with taurine, followed by glycine (McIlvride et al., 2017). Fetal heterogeneous bile acids detected in gallbladder bile and the intestinal contents are mostly consisted of taurocholic acid (TCA) and taurochenodeoxycholic acid (TCDCA), to the extent of about 80 to 90 percent, and the remainder glycocholic acid (GCA) and glycochenodeoxycholic acid (GCDCA). However, it remains uncertain whether those fetal metabolites have impact on the activity and expression of placental hOAT4-mediated uptake of estrogen precursors.

Many studies have indicated that a marked decrease in estrogen, including E1, E2 and E3, together with DHEAS levels may be closely related to the impact of multiple pathologies of the pregnancy, among which intrahepatic cholestasis (ICP) (Kimberly K. L., 2000; Troisi et al., 2003; Chen, 2011; Parizek et al., 2016) and preeclampsia (PE) (Acikgoz et al., 2013; Berkane et al., 2017) have been constantly arousing people's interest and been extensively investigated, yet no consensus has been reached.



Scant information is available concerning the contribution of fetal metabolites on the impact of placental estrogen precursor transporters and the further estrogen synthesis. More detailed information with respect to hOAT4 and its roles during physiological and pathological gestational conditions are to be illustrated.

With those in mind, the purpose of the present study is to substantiate the roles of fetal metabolites, including bilirubin and bile acids, on the inhibition of hOAT4-mediated-uptake of estrogen precursors into placental syncytiotrophoblasts from fetus, and to examine the contribution of fetal metabolites on estradiol synthesis and hOAT4 protein expression at cellular level, using human choriocarcinoma JEG-3 cells and primary human trophoblast cells (PHTCs).

## Materials and Methods

### Materials

Fetal bovine serum (FBS), Dulbecco's modified Eagle's medium (DMEM), Dulbecco's modified Eagle's medium/F12 medium (DF12) were obtained from GIBCO (Invitrogen Life Technologies, USA). 6-carboxylfluorescein (6-CF), Human Serum Albumin (HSA) were purchased from Sigma-Aldrich (St. Louis, MO). Cholic acid (CA), taurocholic acid (TCA), taurochenodeoxycholic acid (TCDCA), glycocholic acid (GCA), glycochenodeoxycholic acid (GCDCA), chenodeoxycholic acid (CDCA), glycodeoxycholic acid (GDCA), taurodeoxycholic acid (TDCA) were provided by Aladdin Co. Ltd (Shanghai, China). Bilirubin (BLB) was gained from Macklin Biochemical Co., Ltd. (Shanghai, China). DHEAS was purchased from Meilun biological Co., Ltd. (Dalian, China). Acetonitrile was obtained from Tedia (Fairfield, TX). Bicinchoninic acid protein assay kit was purchased from Beyotime Institute of Biotechnology (Beyotime, China). Sodium dodecyl sulfonate (SDS) was gained from Amresco (Solon, OH). Anti-SLC22A11 / OAT4 antibody (ab76385) and G418 were obtained from Abcam (Cambridge, MA). Anti-HSD17 $\beta$ 1 antibody (db4038) and Anti-Aromatase antibody (db3890) were provided by diagbio Co. Ltd (Hangzhou, China). Glyceradehyde-3-phosphate dehydrogenase (GAPDH) antibody, and the anti-mouse and anti-rabbit secondary antibodies were purchased from Multi Sciences (Lianke) Biotech Co., Ltd. (Hangzhou, China). Other chemicals or solvents were of the highest grade commercially available.

Blank vector (pEnter), and hOAT4 (SLC22A11) expression plasmid were purchased

from ViGene Biosciences Inc. (Shandong, China.)

## **Cell culture**

Human choriocarcinoma JEG-3 cells were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). Chinese hamster ovary (CHO) cells were kindly provided by Prof. Shuqing Chen, College of Pharmaceutical sciences, Zhejiang University. JEG-3 and CHO cells were cultured in DF12 supplemented with 10% FBS and 1% penicillin/streptomycin in a humidified air/CO<sub>2</sub> incubator (5% v/v).

## **Establishment of stably transfected hOAT4-CHO cell lines**

Recombinant hOAT4-pc3.1 plasmid was constructed successfully from hOAT4-pEnter plasmid purchased from ViGene Biosciences Inc. before CHO cells were seeded in 6-well plates at appropriate density. On day 2, CHO cells were transiently transfected with hOAT4-pc3.1 recombinant plasmid or blank vector (mock) using Lipofectamine 3000 reagent (Invitrogen, Carlsbad, USA) based on the manufacturer's protocol when they reached 60% to 70% confluence. At the following 14 days, the cultured medium of CHO cells transfected with hOAT4-pc3.1 plasmid was replaced every day with the existence of high concentrations of G418 (approx. 900 micrograms / ml). The hOAT4-CHO cells remained were seeded at an exquisite density of 1 / 96 well (1 / 200  $\mu$ L cultured medium). On day 3 after seeding, the stably transfected hOAT4-cell wells were marked and their functions were further validated by comparing the accumulation results of probe substrates in stably-expressed cells with that in mock cells.

## **Cellular accumulation**

The cellular accumulations of 6-CF/DHEAS in JEG-3, hOAT4-CHO cell lines and primary human trophoblast cells (PHTCs) were performed as the method described in our previous study (Bai et al., 2017; Ma et al., 2017). Briefly, the cells were pre-incubated with MES (NaCl, 140 mM; D-glucose, 5.6 mM; KCl, 5.4 mM; MgSO<sub>4</sub>·7H<sub>2</sub>O, 0.8 mM; KH<sub>2</sub>PO<sub>4</sub>, 0.4 mM; CaCl<sub>2</sub>, 1.3 mM; NaHCO<sub>3</sub>, 4.2 mM; Na<sub>2</sub>HPO<sub>4</sub>·12H<sub>2</sub>O, 0.2 mM; 2-Morpholinoethanesulfonic Acid, 10 mM; pH 6.0) buffer at 37 °C for 20 min with or without inhibitors, and then MES buffer containing 6-CF (5 μM)/DHEAS (10 μM) in the absence or presence of inhibitors was added to initiate the accumulation process. This procedure was terminated by adding ice-cold PBS solution quickly at the designated time and removing the incubation buffer. Then the remained bottom cells were washed three times with ice-cold PBS before they were lysed with 100 μM of 0.1 % sodium dodecyl sulfate.

All experiments were performed in triplicate for at least three separate experiments. The concentrations of DHEAS, MTX, BLB, TCDCA, TCA, GCDCA, CDCA in the cells were quantified with LC-MS/MS and then normalized to the total protein content detected with BCA assay in the lysates. The concentrations of 6-CF ( $\lambda_{\text{ex}}$ 490 nm,  $\lambda_{\text{em}}$ 525 nm) were determined by a microplate reader (Spectra Max M2, Molecular Devices, USA). The accumulation results in the presence of inhibitors were expressed as the percentage of the vehicle group (fold of control).

### **Inhibitory effects of fetal metabolites on hOAT4 in PHTCs**

Primary human trophoblast cells were isolated from human uncomplicated placenta delivered at term (38-40 weeks) as the method reported previously with minor

modifications (Bai et al., 2017; Ma et al., 2017; Zeng et al., 2019). Briefly, aliquots of villous from the maternal surface of the placenta were cut away from vessels and washed with PBS containing 1% penicillin-streptomycin for 8-9 times. 500 ml of DMEM containing 25 mM glucose (High Glucose DMEM), 0.07% trypsin and 0.2 mg/mL DNase I (Sigma) were prepared before the digestion periods. Then the tissue was minced and transferred to 200 ml of the DMEM, incubating in a shaking water bath at 37 °C for four different periods of time (30, 30, 15 and 15 min). The third and fourth digestions were mixed and filtered through a nylon mesh, and the pellets were collected after being centrifuged at 2500g for 10 min at 4 °C. The cells were resuspended in 10 mL DMEM medium containing 10% FBS, which was layered over a 5-65% Percoll (GE Healthcare Bio-Sciences, Uppsala, Sweden) gradient at stepwise increments of 5%, and centrifuged at 2500g for 20 min at 4 °C. The cytotrophoblasts in the middle layer were collected and planted at  $1.5 \times 10^6$  cells per well in 12-well plates for culture in DMEM containing 10% FBS. The accumulation assay was performed with the method for JEG cells at 24 h after seeding.

### **Enzyme-linked immunosorbent assays**

Estradiol in the conditioned medium was quantified using a human estradiol enzyme immunoassay kit (Yifeixue Biotechnology, Nanjing, China) based on the manufacturer's protocol. Cells were cultured in 5  $\mu$ M DHEAS with or without the presence of bile acids and bilirubin for 24 hours before the later determination of estradiol secretion. Estradiol concentrations in the conditioned medium and the bottom cells were determined by means of an ELISA. The bottom cells in the 12-well

plate were dissolved in 150  $\mu$ L 0.1 % SDS and then protein content was measured by means of bicinchoninic acid assay to normalize the results.

### **Immunostaining of hOAT4**

The isolated cytotrophoblasts were treated for 24 hours with cultured medium containing DMSO and 2.5  $\mu$ M DMSO 2 hours after the seeding. The bottom cells were washed by PBS for 3 times and placed in fresh 4% neutral-buffered paraformaldehyde before it was probed with antibody against hOAT4 (Abcam, Cambridge, MA), followed by staining with CoraLite 488-conjugated goat anti-rabbit antibodies (proteintech, Wuhan, China). DAPI (4',6-diamidino-2-phenylindole) was then used to identify nuclei. Green labeling indicates hOAT4 positive cells ( $\times 200$ ).

### **Western blot analysis**

Western blot was performed following standard protocols: cells were harvested and lysed using RIPA buffer (Beyotime, Shanghai, China). Protein extracts were subjected to the further SDS-PAGE analysis and subsequently transferred to PVDF membrane (0.45  $\mu$ M, Millipore, MA, USA). The membranes were blocked with 5% non-fat in TBST buffer followed by antibody hybridization and then visualized in Western blotting detection system (LI-COR Biosciences, Lincoln, NE).

### **RNA Isolation, cDNA Synthesis, and Quantitative Real-Time Polymerase Chain Reaction Assays.**

Total RNAs were isolated using RNA simple Total RNA Kit (Tiangen, China) before the cDNAs were synthesized using PrimeScript RT reagent Kit (Takara Bio, Tokyo). And then real-time PCR procedure was performed using SYBR Premix Ex Taq<sup>TM</sup> II

(Takara Bio). Expression of the target mRNAs were normalized to the house-keeping gene GAPDH.

### **LC-MS/MS quantifications of fetal metabolites and DHEAS**

The concentrations of DHEAS and bilirubin in the samples were quantified by an Agilent 1290/6460 LC-MS with a triple quadrupole mass spectrometer (Agilent Technologies, Santa Clara, USA). For DHEAS determination, a 40  $\mu$ L of the cell lysate was mixed with 200  $\mu$ L acetonitrile containing the internal standard (100 nM diclofenac) for 5 min before the mixture was centrifuged at 16,000g for 15 min. The supernatant was further analyzed by LC-MS/MS. Isocratic chromatographic separation was performed on a Porshell C<sub>18</sub> column (2.7  $\mu$ m, 2.1 $\times$ 50 mm) at 30 °C with a gradient elution (0-0.9 min, 90% of A; 0.9-1.1 min, 90-10% of A; 1.1-3.0 min, 10% of A; 3.0-3.2 min, 10-90% of A; 3.2-5.0 min, 90% A), at 0.25 mL/min, where mobile phase A and B were water containing 0.1% formic acid and acetonitrile 0.1% formic acid, respectively. An ESI source was used to conduct mass spectrometric analysis in negative ion mode. Quantification was obtained using multiple reaction monitoring mode at m/z transitions of 367.1 > 367.1 for DHEAS and 295.9 > 251.8 for diclofenac. Fragmentor voltage was set at 190 and 75 V, and collision energy was 5 and 7 V for DHEAS and diclofenac, respectively.

To ascertain if those fetal metabolites were substrates of hOAT4, cellular accumulation of bilirubin/TCDCA/TCA/GCDCA/CDCA samples were measured using the sample preparation method described for the cells mentioned above. Isocratic chromatographic separation for bilirubin was performed on a Porshell C<sub>18</sub>

column (2.7  $\mu$ m, 2.1 $\times$ 50 mm) at 30 °C with a gradient elution (0-0.9 min, 90% of A; 0.9-1.1 min, 90-10% of A; 1.1-3.0 min, 10% of A; 3.0-3.2 min, 10-90% of A; 3.2-5.0 min, 90% A), at 0.25 mL/min, where mobile phase A and B were water and acetonitrile, respectively. Isocratic chromatographic separation for bile acids was performed on a Porshell C<sub>18</sub> column (2.7  $\mu$ m, 2.1 $\times$ 50 mm) at 30 °C with a gradient elution (0-1.5 min, 80% of A; 1.5-2.0 min, 80-40% of A; 2.0-3.0 min, 40% of A; 3.0-5.0 min, 40-80% of A; 3.2-5.0 min, 80% A), at 0.25 mL/min, where mobile phase A and B were water and acetonitrile, respectively. A negative-ion-mode ESI source was used for mass spectrometric analysis. Quantifications were obtained at m/z transitions of 295.9 > 251.8 for diclofenac (internal standard for bilirubin), 583.3 > 285 for bilirubin, 407 > 343 for CA (internal standard for bile acids), 514 > 124 for TCA, 498 > 124 for TCDCA, 391.2 > 391.2 for CDCA, 448.3 > 74 for GCDCA. Fragmentor voltage was set at 75, 150, 280, 150, 275, 250 and 200 V, and collision energy was 7, 22, 10, 10, 10, 0, 35V for diclofenac, bilirubin, CA, TCA, TCDCA, CDCA and GCDCA, respectively.

The methods were validated according to Food and Drug Administration guidelines and satisfied specificity, precision (inter- and intra-assay), accuracy (inter- and intra-assay) and matrix effect were demonstrated.

### **Data analysis.**

Data are expressed as mean  $\pm$  SD. *In-vitro* experiments were conducted at least three times in triplicate. Unpaired Student's t test was performed between two groups and one-way analysis of variance followed with Dunnett's or Tukey's post hoc test was



applied for more than two groups through the GraphPad Prism version 8.0 analysis. P values  $< 0.05$  were considered statistically significant.

## Results

### Fetal metabolites were identified to be the inhibitors of hOAT4

OAT4 is one of the most abundantly expressed SLC transporters in human placenta facing the fetal side and plays important roles in the uptake of fetal derived DHEAS and 16 $\alpha$ -OH-DHEAS for the followed estrogen synthesis. Here we investigated whether those fetal metabolites such as bilirubin and bile acids have inhibitory effects on OAT4 activity. As shown in **Fig. 1**, bilirubin (BLB), whose metabolism and excretion in fetus is much less efficient than that in the adult due to the immaturity of fetal liver, had fascinatingly intense inhibitory effects on the accumulation of 6-CF (a known substrate of hOAT4) in stably transfected hOAT4-CHO cells with the IC<sub>50</sub> value reaching up to 1.53  $\mu$ M (**Fig.1a**). Additionally, bile acids in the fetal compartment including TCDCA, GCDCA, TCA and CDCA reduced the hOAT4-mediated uptake of 6-CF, with the IC<sub>50</sub> values of 90.2, 129, 16.4 and 12.3  $\mu$ M, respectively (**Fig. 1b-e**). Other tested bile acids like GCA, CA, TDCA and GDCA may not have impact on the transport activity of hOAT4 (**Fig. 1f**). Despite the inhibitory roles of those fetal metabolites confirmed above, they are not substrates of hOAT4 based on their accumulation data in mock and hOAT4-CHO cells with or without the existence of probenecid (100  $\mu$ M), an identified OAT4 inhibitor (**Fig. 1g**). Additionally, bilirubin seems not to have impact on other OAT transporters including OAT1, OAT2 and OAT3 (**Fig. 1i-k**), thus bilirubin is potentially a specific inhibitor of OAT4.

### Fetal metabolites inhibited hOAT4-mediated uptake of estrogen precursors

Since hormones derived from the placenta play a critical role in establishment and subsequent progression of human pregnancy, it dramatically aroused our interest to investigate whether those metabolites play roles on the hOAT4-mediated transport of estrogen precursors and subsequently reducing the estrogen synthesis. Considering that unconjugated bilirubin generally binds with albumin, to examine the inhibitory effects on hOAT4-mediated uptake of substrates in the mimic real fetal compartment, we conducted the accumulation procedure of 6-CF and estrogen precursor DHEAS at varied molar ratios of bilirubin/albumin (Ahlfors and Wennberg, 2004; Sebastian D. C., 2007; Morioka et al., 2015) with the presence of 10  $\mu$ M (**Fig 2**) human serum albumin (HSA) in the accumulation buffer.

As shown in this section, bilirubin-albumin system containing bilirubin with concentrations ranging from 0.625 to 10  $\mu$ M in the presence of 10  $\mu$ M HSA buffer performed significant inhibitory effects on the accumulation of 6-CF (reduced by 60%, at 10  $\mu$ M,  $P < 0.001$ , **Fig. 2a**) and estrogen precursor DHEAS (reduced by 80%, at 10  $\mu$ M,  $P < 0.001$ , **Fig. 2b**) in hOAT4-CHO cells with the  $IC_{50}$  value of 0.98  $\mu$ M for DHEAS, but exerted little inhibitory effects on OATP2B1 (**Fig. S2**).

Moreover, bile acids, including TCDCA, GCDCA, CDCA and TCA showed relatively weaker yet concentration-dependent inhibitory effects on the accumulation of DHEAS in hOAT4-CHO cells ( $P < 0.05$ , **Fig. 2c**).

### **Fetal metabolites inhibited the accumulation of DHEAS in JEG-3 and PHTCs**

To further confirm the roles of fetal metabolites on hOAT4-mediated transport through placenta, we measured the inhibitory effects of bilirubin on the accumulation

of DHEAS in JEG-3, a well-characterized immortalized human trophoblast choriocarcinoma cell line. As shown in **Fig. 3a**, bilirubin potently reduced the accumulation of DHEAS in the presence of 10  $\mu$ M HSA in JEG-3 in a concentration-dependent manner (reduced by 60 %, at 10  $\mu$ M,  $P < 0.001$ ). PHTCs (primary human trophoblast cells) were utilized to further assess the inhibitory roles of those metabolites. The results revealed that bilirubin-albumin system containing 10  $\mu$ M HSA exhibited obviously concentration-dependent inhibitory effects on the accumulation of the estrogen precursor DHEAS in PHTCs (reduced by 80%, bilirubin at 10  $\mu$ M,  $P < 0.001$ , **Fig. 3b**).

Besides, fetal bile acids (100  $\mu$ M) including TCDCA, GCDCA, TCA and CDCA did perform a certain impact on the accumulation of DHEAS in PHTCs (**Fig. 3d**).

### **Bilirubin reduced the estradiol synthesis and secretion from PHTCs**

The PHTCs were further utilized to ascertain estradiol secretion inhibition roles of those metabolites mentioned above in placenta, as illustrated in Fig. 4. Cells were pre-cultured with 5  $\mu$ M DHEAS with or without bilirubin or bile acids for 24 hours before the later determination of estradiol secretion. As shown in Fig.4, estradiol concentrations in the medium (**Fig. 4a**) and cells (**Fig. 4b**) were concentration-dependently inhibited by bilirubin pretreatment, among which 2.5  $\mu$ M bilirubin reduced the synthesis of estradiol by 30 % and secretion by 35 %. We further confirmed that bile acids (50  $\mu$ M) showed marginal inhibitory effects on the secretion of estradiol in PHTCs ( $P < 0.05$ , **Fig. 4c**).

### **Bilirubin down-regulated the hOAT4 protein expression in PHTCs**

To further explore whether bilirubin performed down-regulation roles in such E2 suppressing procedure, the cells were carefully collected for further determinations of hOAT4 protein expression through immunostaining and Western Blot after pretreatment with bilirubin ranging from 0.625 to 2.5  $\mu$ M for 24 hours. Bilirubin reduced the immune fluorescence intensity of hOAT4 (**Fig. 5a**) and inhibited hOAT4 protein expression in a concentration-dependent manner (**Fig. 5b**). The protein and mRNA expressions of those steroidogenic enzymes involved in the synthesis and metabolism of estradiol were determined and of little difference (**Fig. 5b-c**), indicating that they contributed little to the lowering of estradiol secretion in PHTCs. The hOAT4 protein expression in PHTCs pretreated with bilirubin were down-regulated, while the mRNA expression (**Fig. 5c**) seemed not to be altered, suggesting post-translational modifications may be involved in this process.

## Discussion

This study gave solid evidence that bilirubin in the fetal compartment exhibited significant inhibitory effects on hOAT4-mediated estrogen precursor DHEAS transport in hOAT4-CHO cells, JEG-3 and PHTCs. Bilirubin concentration-dependently suppressed the estradiol synthesis and secretion in PHTCs, which was synchronized with the decline of hOAT4 protein expression. Additionally, those identified bile acids rendered a weaker inhibitory tendency in transporting hOAT4-mediated substrates.

The hOAT4-mediated uptake of DHEAS (Seok Ho Cha, 2000; Ugele et al., 2008) and 16 $\alpha$ -OH-DHEAS (Schweigmann et al., 2014; Tomi et al., 2015) showed saturable kinetics and followed the Michaelis-Menten equation with nonlinear regression analysis yielding  $K_m$  values of  $29.2 \pm 3.4$  and  $7.35 \pm 3.5$   $\mu$ M and  $V_{max}$  values of  $620 \pm 71$  and  $85.5 \pm 22.2$  pmol/mg protein /min. DHEAS is transported by hOAT4 and hOATP2B1 for further metabolism to estrone (E1) and estradiol (E2), while 16 $\alpha$ -OH-DHEAS accumulation is only mediated by hOAT4 to be further transformed to estriol (E3). Although hOATP2B1 is highly expressed in PHTCs and placenta, the affinity of DHEAS toward OATP2B1 ( $K_m$  of 210.8  $\mu$ M,  $V_{max}$  of 602 pmol/mg protein/min) was about 10 times lower than that in hOAT4. Thus we assumed that hOAT4 plays an essential role in the accumulation of estrogen precursors during pregnancy and the inhibitory effects of fetal metabolites on hOAT4-mediated substrate uptake provide a novel insight into the correlation between abnormal fetal derived waste with maternal estrogen levels.

Orthologs of OAT4 are found only in human, but not in rodents (Seok Ho Cha, 2000), which makes it impossible to conduct animal-based studies for further illuminations of hOAT4. Total bilirubin concentration in fetal blood ranged from 3.2 to 19.5  $\mu\text{M}$  (S Nava, 1996; Sikkil et al., 2004), in which case the conjugated bilirubin concentration was less than 10 % of the total bilirubin concentration. As illustrated before, fetal bilirubin is mostly composed of unconjugated bilirubin binding to serum albumin or  $\alpha$ -fetoprotein, and plasma unbound free bilirubin levels at any given total bilirubin or bilirubin/albumin ratio can vary widely due to varying concentrations of albumin. At a given total bilirubin, 30  $\mu\text{M}$  HSA and 10 % (vol/vol) FBS yielded comparable free bilirubin values (Sebastian D. C., 2007). Bilirubin-albumin system containing 0.01 to 10  $\mu\text{M}$  bilirubin in the presence of 10  $\mu\text{M}$  human serum albumin (HSA) buffer revealed evident concentration-dependent inhibitory effects on the accumulation of 6-CF as well as estrogen precursor DHEAS (**Fig.2-3**) in hOAT4-CHO cells while performing no influence on OATP2B1 (**Fig. S2**). Mean fetal total bile acid concentration reached 3.6  $\mu\text{M}$  (range 3.1-4.1) (Estiu et al., 2015) and 2.2  $\mu\text{M}$  (range 1.8-2.9) (Vasavan et al., 2021). TCDCA and TCA make up 80-90 percent of total fetal bile acid profile, and bile acids including TCDCA, GCDCA, TCA, CDCA showed minor inhibitory effects on the probe substrates of hOAT4 (**Fig. 2c and Fig. S1a**), which is partly in accordance with the former study (Seok Ho Cha, 2000).

Considering the vulnerability and sensitivity of PHTCs against bilirubin, we set the highest concentration as 2.5  $\mu\text{M}$  in the later 24 hours of culture to attain the bottom cells and the upper medium for estradiol determinations (**Fig. 4a-b**), the

immunostaining and WB conductions (**Fig. 5a-b**), rather than 10  $\mu$ M in the former temporary 3-minute accumulation examinations (**Fig. 2-3**). We confirmed that bilirubin significantly suppressed the estradiol synthesis and secretion through inhibiting the transporting activity and protein expression of hOAT4 in PHTCs (**Fig. 4-5**). Previous studies(Samson et al., 2009) have indicated that aromatase, 17 beta-hydroxysteroid dehydrogenase 1 (HSD17 $\beta$ 1) that are highly expressed in placenta are the enzymes responsible for the transformation of DHEAS into E2. The protein and mRNA expressions of those steroidogenic enzymes involved in the synthesis and metabolism (J Andrew Williams, 2002; Niwa et al., 2015; Chatuphonprasert et al., 2018) of estradiol were determined and of little difference (**Fig. 5b-c**), which suggested that they contributed little to the lowering of estradiol secretion in PHTCs. In addition, it has been reported that OATPs (OATP1A2 and OATP1B1 in the apical membrane and OATP2B1 in the basal membrane) also transport DHEAS (Hagenbuch and Gui, 2008). Though former studies have identified that OATP1A2, OATP1B1 and OATP1B3 contribute to the bilirubin uptake (Oscar B., 2003), they were rarely expressed in the isolated PHTCs (**Fig. 5c**). The activity of the OATP transporter highly expressed in PHTCs, OATP2B1(**Fig. 5c**), seemed not to be inhibited by bilirubin (**Fig. S2**). Additionally, bilirubin dramatically inhibited the DHEAS accumulation in JEG-3 cells in this study (**Fig. 3c**), which exclusively expressed OAT4 (**Fig. S1b**). Given the above, we speculated that bilirubin had little influence on the DHEAS uptake by OATPs. Considering that a wide range of endogenous bile acids are substrates or inhibitors of OATPs, bile acids may inhibit



both OAT4- and OATPs- dependent DHEAS uptake in PHTCs (**Fig. 3d**).

Despite the inhibitory roles of those fetal metabolites confirmed above and the overlap of substrates for OATs, they are not substrates of hOAT4 based on their accumulation in mock and hOAT4-CHO cells with or without the existence of the classic OAT inhibitor probenecid. Besides, bilirubin seems not to have inhibitory impact on other OAT transporters including OAT1, OAT2 and OAT3 (**Fig 1i-k**) based on the substrate-accumulation study in the absence or presence of bilirubin, thus bilirubin is potentially a specific inhibitor of OAT4.

Fetal albumin binds to bilirubin, cysteine, free fatty acids, calcium and drugs, with its concentration serving as a marker of nutritional status. Recently, studies focusing on the measurement of maternal serum ischemia-modified albumin (IMA) and fetal cord-blood IMA concentrations have suggested IMA as simple, novel, and inexpensive markers of oxidative stress (OS) status in preeclampsia patients (van Rijn et al., 2008; Rossi et al., 2013; Seshadri Reddy et al., 2018). The disruption on the synthesis of fetal albumin or unintended IMA may lead to a disorder of unconjugated bilirubin concentrations, thus causing hOAT4 activity and expression inhibition.

Maintenance of a healthy pregnancy is dependent on a coordinated sequence of events, including synchrony between the development of the early embryo and establishment of a receptive endometrium. Estradiol and estriol concentrations in maternal serum and urine rise steadily from the first trimester until delivery and diminish rapidly in the post-partum period (Kuijper et al., 2013), and to achieve this, syncytiotrophoblasts require efficient DHEAS and 16 $\alpha$ -OH-DHEAS uptake at the basal membrane (BM)

facing the fetal circulation. Increased production of estrogen in human placenta during pregnancy closely associates with parturition, therefore, maternal estradiol and estriol levels are frequently used as quad marker screening to monitor for placental and fetal abnormalities. Preeclampsia (PE) with the feature of high blood pressure occurs in 3% to 7% of pregnancies and is one of the main causes of maternal and fetal/neonatal morbidity and mortality. Levels of estrogens including E1 (Jobe et al., 2013), E2 (Smith et al., 2009; Bussen and Bussen, 2011; Jobe et al., 2013; Yin et al., 2013) and E3 (Smith et al., 2009; Hertig et al., 2010; Jobe et al., 2013), their precursors like DHEAS (Hertig et al., 2010), and their byproducts were suppressed in the plasma of women with pregnancy-related hypertensive diseases. Furthermore, E2 and E3 levels were significantly lower (Acikgoz et al., 2013) in preeclampsia placental tissues than in tissues from women with normal pregnancies. Although rare studies focused on monitoring the fetal / cord blood bilirubin levels during physiological pregnancy or pathological complications, we did observe a trend of higher bilirubin level in the umbilical cord blood from preeclampsia pregnancies (Catarino et al., 2009). The estrogen deficiency occurring during those multisystem disorders (Kimberly K. L., 2000; Troisi et al., 2003; Chen, 2011; Acikgoz et al., 2013; Kuijper et al., 2013; Parizek et al., 2016; Berkane et al., 2017) mentioned above strengthens our assumptions that impaired fetal albumin synthesis or abnormally higher bilirubin concentrations may contribute to the lowering levels of estrogen in the unintended preeclampsia development. Additionally, what roles uric acid (an identified substrate and inhibitor for hOAT4), bilirubin or bile acid levels in preeclampsia along with

maternal hyperuricemia (Lam et al., 2005; Powers et al., 2006; Khaliq et al., 2018; Ryu et al., 2019), hyperbilirubinemia (Duraismamy et al., 2017) or ICP (Raz et al., 2015; Liu et al., 2020) conditions play on the placental hOAT4 activity, expression, estrogen levels together with pregnancy progression remain to be further explored.

Considering the essential role of hOAT4 in the uptake of estriol precursor  $16\alpha$ -OH DHEAS, we have made every effort to get in touch with all kinds of suppliers seeking for possible commercialized  $16\alpha$ -OH-DHEAS, but failed to attain it. The intriguing role of fetal metabolites on hOAT4-mediated uptake of  $16\alpha$ -OH-DHEAS for later estriol synthesis remains to be illuminated.

In conclusion, this study demonstrated that bilirubin reduced the uptake of estrogen precursors and the followed synthesis of estradiol in isolated primary human trophoblast cells (PHTCs) *via* inhibition and down-regulation of OAT4. More profound studies concerning specific roles of hOAT4 in the development of preeclampsia or other gestational complications remain to be further illustrated.

## **Acknowledgements**

We thank Ms. Haihong Hu for managing some instruments.

### **Authors' contributions**

Participated in research design: Zhang, and Jiang.

Conducted experiments: Zhang, Chen, Dai, Bai, and Lu.

Performed data analysis: Zhang, Zhou, and Jiang.

Wrote or contributed to the writing of the manuscript: Zhang, and Jiang.

## References

- Acikgoz S, Bayar UO, Can M, Guven B, Mungan G, Dogan S, and Sumbuloglu V (2013) Levels of oxidized LDL, estrogens, and progesterone in placenta tissues and serum paraoxonase activity in preeclampsia. *Mediators Inflamm* **2013**:862982.
- Ahlfors CE and Wennberg RP (2004) Bilirubin-albumin binding and neonatal jaundice. *Semin Perinatol* **28**:334-339.
- Bai M, Ma Z, Sun D, Zheng C, Weng Y, Yang X, Jiang T, and Jiang H (2017) Multiple drug transporters mediate the placental transport of sulpiride. *Arch Toxicol* **91**:3873-3884.
- Berkane N, Liere P, Oudinet JP, Hertig A, Lefevre G, Pluchino N, Schumacher M, and Chabbert-Buffet N (2017) From Pregnancy to Preeclampsia: A Key Role for Estrogens. *Endocr Rev* **38**:123-144.
- Bussen S and Bussen D (2011) Influence of the vascular endothelial growth factor on the development of severe pre-eclampsia or HELLP syndrome. *Arch Gynecol Obstet* **284**:551-557.
- Catarino C, Rebelo I, Belo L, Rocha-Pereira P, Rocha S, Bayer Castro E, Patricio B, Quintanilha A, and Santos-Silva A (2009) Erythrocyte changes in preeclampsia: relationship between maternal and cord blood erythrocyte damage. *J Perinat Med* **37**:19-27.
- Chatuphonprasert W, Jarukamjorn K, and Ellinger I (2018) Physiology and Pathophysiology of Steroid Biosynthesis, Transport and Metabolism in the Human Placenta. *Front Pharmacol* **9**:1027.
- Chen CWX (2011) Impaired fetal adrenal function in intrahepatic cholestasis of pregnancy. *Medical Science Monitor* **17**:265-271.
- Colombo C. ZG, Ronchi M., Breidenstein J. (1988) Hepatic Bile Acid Metabolism during Early Development Revealed from the Analysis of Human Fetal Gallbladder Bile. *THE JOURNAL OF BIOLOGICAL CHEMISTRY* **263**:16637-16644.

- Duraiswamy S, Sheffield JS, McIntire D, Leveno K, and Mayo MJ (2017) Updated Etiology and Significance of Elevated Bilirubin During Pregnancy: Changes Parallel Shift in Demographics and Vaccination Status. *Dig Dis Sci* **62**:517-525.
- Estiu MC, Monte MJ, Rivas L, Moiron M, Gomez-Rodriguez L, Rodriguez-Bravo T, Marin JJ, and Macias RI (2015) Effect of ursodeoxycholic acid treatment on the altered progesterone and bile acid homeostasis in the mother-placenta-foetus trio during cholestasis of pregnancy. *Br J Clin Pharmacol* **79**:316-329.
- Hagenbuch B and Gui C (2008) Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. *Xenobiotica* **38**:778-801.
- Hertig A, Liere P, Chabbert-Buffet N, Fort J, Planos A, Eychenne B, Cambourg A, Schumacher M, Berkane N, Lefevre G, Uzan S, Rondeau E, Rozenberg P, and Rafestin-Oblin ME (2010) Steroid profiling in preeclamptic women: evidence for aromatase deficiency. *Am J Obstet Gynecol* **203**:477 e471-479.
- J Andrew Williams BJR, Varon E Cantrell (2002) Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes. *Drug Metab Dispos* **30**:1266-1273.
- Jobe SO, Tyler CT, and Magness RR (2013) Aberrant synthesis, metabolism, and plasma accumulation of circulating estrogens and estrogen metabolites in preeclampsia implications for vascular dysfunction. *Hypertension* **61**:480-487.
- Khaliq OP, Konoshita T, Moodley J, and Naicker T (2018) The Role of Uric Acid in Preeclampsia: Is Uric Acid a Causative Factor or a Sign of Preeclampsia? *Curr Hypertens Rep* **20**:80.
- Kimberly K. L. LR (2000) Estrogens in Intrahepatic Cholestasis of Pregnancy. *Obstetricians and Gynecologists* **95**:372-376.
- Kuijper EA, Ket JC, Caanen MR, and Lambalk CB (2013) Reproductive hormone concentrations in pregnancy and neonates: a systematic review. *Reprod Biomed Online* **27**:33-63.
- Lam C, Lim KH, Kang DH, and Karumanchi SA (2005) Uric acid and preeclampsia. *Semin Nephrol* **25**:56-60.

- Liu C, Gao J, Liu J, Wang X, He J, Sun J, Liu X, and Liao S (2020) Intrahepatic cholestasis of pregnancy is associated with an increased risk of gestational diabetes and preeclampsia. *Ann Transl Med* **8**:1574.
- Ma Z, Yang X, Jiang T, Bai M, Zheng C, Zeng S, Sun D, and Jiang H (2017) Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. *Drug Metab Dispos* **45**:269-278.
- Macias RI, Marin JJ, and Serrano MA (2009) Excretion of biliary compounds during intrauterine life. *World J Gastroenterol* **15**:817-828.
- McIlvride S, Dixon PH, and Williamson C (2017) Bile acids and gestation. *Mol Aspects Med* **56**:90-100.
- Morel Y, Roucher F, Plotton I, Goursaud C, Tardy V, and Mallet D (2016) Evolution of steroids during pregnancy: Maternal, placental and fetal synthesis. *Ann Endocrinol (Paris)* **77**:82-89.
- Morioka I, Iwatani S, Koda T, Iijima K, and Nakamura H (2015) Disorders of bilirubin binding to albumin and bilirubin-induced neurologic dysfunction. *Semin Fetal Neonatal Med* **20**:31-36.
- Naritaka N, Suzuki M, Sato H, Takei H, Murai T, Kurosawa T, Iida T, Nittono H, and Shimizu T (2015) Profile of bile acids in fetal gallbladder and meconium using liquid chromatography-tandem mass spectrometry. *Clin Chim Acta* **446**:76-81.
- Niwa T, Murayama N, Imagawa Y, and Yamazaki H (2015) Regioselective hydroxylation of steroid hormones by human cytochromes P450. *Drug Metab Rev* **47**:89-110.
- Oscar B. MAS, Rocio I. R. (2003) Role of organic anion-transporting polypeptides, OATP-A, OATP-C and OATP-8, in the human placenta-maternal liver tandem excretory pathway for foetal bilirubin. *Biochem J* **371**:897-905.
- Parizek A, Hill M, Duskova M, Vitek L, Velikova M, Kancheva R, Simjak P, Koucky M, Kokrdova Z, Adamcova K, Cerny A, Hajek Z, and Starka L (2016) A Comprehensive Evaluation of Steroid Metabolism in Women with Intrahepatic Cholestasis of Pregnancy. *PLoS One* **11**:e0159203.
- Pasqualini JR (2005) Enzymes involved in the formation and transformation of



steroid hormones in the fetal and placental compartments. *J Steroid Biochem Mol Biol* **97**:401-415.

Powers RW, Bodnar LM, Ness RB, Cooper KM, Gallaher MJ, Frank MP, Daftary AR, and Roberts JM (2006) Uric acid concentrations in early pregnancy among preeclamptic women with gestational hyperuricemia at delivery. *Am J Obstet Gynecol* **194**:160.

Raz Y, Lavie A, Vered Y, Goldiner I, Skornick-Rapaport A, Landsberg Asher Y, Maslovitz S, Levin I, Lessing JB, Kuperminc MJ, and Rimon E (2015) Severe intrahepatic cholestasis of pregnancy is a risk factor for preeclampsia in singleton and twin pregnancies. *Am J Obstet Gynecol* **213**:395 e391-398.

Rossi A, Bortolotti N, Vescovo S, Romanello I, Forzano L, Londero AP, Ambrosini G, Marchesoni D, and Curcio F (2013) Ischemia-modified albumin in pregnancy. *Eur J Obstet Gynecol Reprod Biol* **170**:348-351.

Ryu A, Cho NJ, Kim YS, and Lee EY (2019) Predictive value of serum uric acid levels for adverse perinatal outcomes in preeclampsia. *Medicine (Baltimore)* **98**:e15462.

S Nava LB, G Zuliani (1996) Aspects of fetal physiology from 18 to 37 weeks' gestation as assessed by blood sampling. *Obstet Gynecol* **87**:975-980.

Samson M, Labrie F, and Luu-The V (2009) Specific estradiol biosynthetic pathway in choriocarcinoma (JEG-3) cell line. *J Steroid Biochem Mol Biol* **116**:154-159.

Schweigmann H, Sanchez-Guijo A, Ugele B, Hartmann K, Hartmann MF, Bergmann M, Pfarrer C, Doring B, Wudy SA, Petzinger E, Geyer J, and Grosser G (2014) Transport of the placental estriol precursor 16alpha-hydroxy-dehydroepiandrosterone sulfate (16alpha-OH-DHEAS) by stably transfected OAT4-, SOAT-, and NTCP-HEK293 cells. *J Steroid Biochem Mol Biol* **143**:259-265.

Sebastian D. C. CB, Pablo G. (2007) Cytotoxicity Is Predicted by Unbound and Not Total Bilirubin Concentration. *PEDIATRIC RESEARCH* **62**:576-580.

Seok Ho Cha TS, Hiroyuki Kusuhara (2000) Molecular Cloning and Characterization of Multispecific Organic Anion Transporter 4 Expressed in the Placenta. *THE*

*JOURNAL OF BIOLOGICAL CHEMISTRY* **275**:4507-4512.

- Seshadri Reddy V, Duggina P, Vedhantam M, Manne M, Varma N, and Nagaram S (2018) Maternal serum and fetal cord-blood ischemia-modified albumin concentrations in normal pregnancy and preeclampsia: a systematic review and meta-analysis. *J Matern Fetal Neonatal Med* **31**:3255-3266.
- Sikkel E, Pasman SA, Oepkes D, Kanhai HH, and Vandenbussche FP (2004) On the origin of amniotic fluid bilirubin. *Placenta* **25**:463-468.
- Smith R, Smith JI, Shen X, Engel PJ, Bowman ME, McGrath SA, Bisits AM, McElduff P, Giles WB, and Smith DW (2009) Patterns of plasma corticotropin-releasing hormone, progesterone, estradiol, and estriol change and the onset of human labor. *J Clin Endocrinol Metab* **94**:2066-2074.
- Tomi M, Eguchi H, Ozaki M, Tawara T, Nishimura S, Higuchi K, Maruyama T, Nishimura T, and Nakashima E (2015) Role of OAT4 in Uptake of Estriol Precursor 16alpha-Hydroxydehydroepiandrosterone Sulfate Into Human Placental Syncytiotrophoblasts From Fetus. *Endocrinology* **156**:2704-2712.
- Troisi R, Potischman N, Roberts JM, Ness R, Crombleholme W, Lykins D, Siiteri P, and Hoover RN (2003) Maternal serum oestrogen and androgen concentrations in preeclamptic and uncomplicated pregnancies. *Int J Epidemiol* **32**:455-460.
- Ugele B, Bahn A, and Rex-Haffner M (2008) Functional differences in steroid sulfate uptake of organic anion transporter 4 (OAT4) and organic anion transporting polypeptide 2B1 (OATP2B1) in human placenta. *J Steroid Biochem Mol Biol* **111**:1-6.
- van Rijn BB, Franx A, Sikkema JM, van Rijn HJ, Bruinse HW, and Voorbij HA (2008) Ischemia modified albumin in normal pregnancy and preeclampsia. *Hypertens Pregnancy* **27**:159-167.
- Vasavan T, Deepak S, Jayawardane IA, Lucchini M, Martin C, Geenes V, Yang J, Lovgren-Sandblom A, Seed PT, Chambers J, Stone S, Kurlak L, Dixon PH, Marschall HU, Gorelik J, Chappell L, Loughna P, Thornton J, Pipkin FB, Hayes-Gill B, Fifer WP, and Williamson C (2021) Fetal cardiac dysfunction in intrahepatic cholestasis of pregnancy is associated with elevated serum bile acid

concentrations. *J Hepatol* **74**:1087-1096.

Yin G, Zhu X, Guo C, Yang Y, Han T, Chen L, Yin W, Gao P, Zhang H, Geng J, Wang J, and Liang L (2013) Differential expression of estradiol and estrogen receptor alpha in severe preeclamptic pregnancies compared with normal pregnancies. *Mol Med Rep* **7**:981-985.

Yutaka Aoyagi TI (1979)  $\alpha$ -Fetoprotein as a Carrier Protein in Plasma and Its Bilirubin-binding Ability. *Cancer Research Vol* **39**:3571-3574.

Zeng Q, Bai M, Li C, Lu S, Ma Z, Zhao Y, Zhou H, Jiang H, Sun D, and Zheng C (2019) Multiple Drug Transporters Contribute to the Placental Transfer of Emtricitabine. *Antimicrob Agents Chemother* **63**.

### **Conflict of interest**

The authors declare that they have no conflicts of interest.

### **Ethical standards**

The primary human trophoblast cell studies have been approved by the Ethics Committee of Women's Hospital, College of Pharmaceutical sciences, Zhejiang University. And all pregnant women signed their informed consent prior to the experiment.

### **Footnote**

This work was supported by National Natural Science Foundation of China [Grant Nos. 81773804, 82003838] and Zhejiang Province Natural Science Foundation of China [Grant No. LY22H310006].

## Figure Legends

**Fig. 1** Identification of inhibitors and substrates of OAT4 from fetal metabolites, including (a) Bilirubin (BLB), (b) TCDCA, (c) GCDCA, (d) TCA, and (e) CDCA. (f) Tested bile acids that are not inhibitors of hOAT4 were listed. The accumulation was expressed as percent or fold of 6-CF (5  $\mu$ M) without the fetal metabolites in hOAT4-CHO cells. Compared with the hOAT4-CHO cells without probenecid (CON), \*\*\*P < 0.001. (g) The accumulations of fetal metabolites (50  $\mu$ M) in mock and hOAT4-CHO cells. The accumulation was expressed as fold of 6-CF (5  $\mu$ M), DHEAS (10  $\mu$ M) or tested fetal metabolites in mock cells without probenecid (100  $\mu$ M). (h) Quantitative real-time PCR (RT-qPCR) was carried out to identify the expression of hOAT4 mRNA in hOAT4-CHO cells. (i-k) Identifications of the bilirubin inhibitory effects on OAT1-MDCK, OAT2-MDCK and OAT3-HEK stably transfected cells constructed and preserved in our laboratory. Functions of tested OAT1-3 cells have been previously identified by their probe substrates (5  $\mu$ M 6-CF, 10  $\mu$ M cGMP and 5  $\mu$ M 6-CF respectively). Compared with the mock cells, \*\*\*P < 0.001; compared with the hOAT4-CHO cells without probenecid, ###P < 0.001. Data were expressed as mean  $\pm$  SD from three independent experiments conducted in triplicate.

**Fig. 2** The inhibitory effects of fetal metabolites on the uptake of 6-CF (5  $\mu$ M) or estrogen precursor DHEAS (10  $\mu$ M) in hOAT4-CHO cells. Bilirubin - albumin system performed inhibitory effects on the accumulation of (a) 6-CF and (b) DHEAS in hOAT4-CHO cells in the presence of 10  $\mu$ M HSA. Compared with the substrate uptake in hOAT4-CHO cells without inhibitors (CON), \*P < 0.05, \*\*P < 0.01, \*\*\*P <

0.001. (c) Bile acids performed weaker inhibitory effects on the uptake of DHEAS in hOAT4-CHO cells. Compared with the uptake in hOAT4-CHO cells without BLB or bile acids (CON), \*P < 0.05. The accumulation was expressed as fold of CON. All cells were incubated at 37 °C for 3 minutes. Data were expressed as mean ± SD, from three independent experiments conducted in triplicate.

**Fig. 3** Inhibitory effects on hOAT4-mediated uptake of DHEAS (10 μM) in JEG-3 cell lines and PHTCs by bilirubin and bile acids. Bilirubin with different concentrations in the presence of 10 μM HSA showed inhibitory effects on DHEAS accumulation in JEG-3 (a) and PHTCs (b). Bile acids including TCDCA, GCDCA, TCA and CDCA (100 μM) performed relatively weaker inhibitory effects on the accumulation of DHEAS in JEG-3 (c) and PHTCs (d). Compared with the accumulation without BLB or bile acids (CON) . \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001. All cells were incubated at 37 °C for 3 minutes. The accumulation was expressed as fold of CON. Data were expressed as mean ± SD from three independent experiments conducted in triplicate.

**Fig. 4** Bilirubin (BLB) or bile acids reduced estradiol concentration in cultural medium (a, c) and PHTCs (b). Cells were cultured with DHEAS (5 μM) in the absence or presence of bilirubin / bile acids (50 μM) at 37 °C for 24 hours. Estradiol concentrations in the medium cells were determined by means of an ELISA. Compared with the control group without BLB or bile acids (CON), \*P < 0.05, \*\*\*P < 0.001. Data were expressed as mean ± SD, from three independent experiments conducted in triplicate.



**Fig. 5** Representative results for (a) immunostaining and (b) Western Blot protein expression of hOAT4 in PHTCs pretreated with bilirubin (BLB). (c) The mRNA expression of hOAT4 and the steroidogenic enzymes involved in the synthesis and metabolism of estradiol in PHTCs. Relative mRNA levels of target genes were normalized by *hGAPDH*, using the  $\Delta\text{Ct}$  method and described as  $2^{-\Delta\text{Ct}}$ ,  $\Delta\text{Ct}$  = average Ct (target gene)-average Ct (GAPDH). All cells were pre-incubated with or without bilirubin at 37 °C for 24 hours (without DHEAS) before the performance of immunostaining and Western Blot. DAPI (4',6-diamidino-2-phenylindole) was used to identify nuclei. Data were expressed as mean  $\pm$  SD, n=3. Compared with control cells treated with DMSO. Data were obtained from three independent experiments conducted in triplicate.





Fig. 1

**Fig. 2**




Fig. 3




Fig. 4




Fig. 5